# Venetoclax combined with dose-reduced HAD as induction treatment for patients with de-novo acute myeloid leukemia

## TL;DR

This study evaluates the effectiveness and safety of combining Venetoclax with a reduced-dose HAD regimen for treating newly diagnosed acute myeloid leukemia.

## Contribution

The novel contribution is demonstrating high remission rates and safety using Venetoclax with reduced-dose HAD in AML patients.

## Key findings

- One course of treatment achieved an 84% complete remission rate.
- The one-year overall survival rate was 100%.
- The regimen showed high efficacy and good safety in AML patients.

## Abstract

通过回顾性分析自2022年5月至2023年1月收治的25例初诊急性髓系白血病（AML）患者，探索应用维奈克拉联合减低剂量HAD（高三尖杉酯碱+柔红霉素+阿糖胞苷）方案诱导治疗初诊AML的疗效及安全性。按照ELN 2017预后分层标准，低危组13例（52.0％），中危组3例（12.0％），高危组9例（36.0％）。1个疗程诱导治疗总体有效率（完全缓解率+部分缓解率）88.0％，1个疗程完全缓解率84.0％。截至2023年5月30日，中位随访9个月，全部患者诱导治疗后给予巩固治疗2（1～5）个周期。1年总生存率、无事件生存率、无复发生存率分别为100％、94.7％、94.7％。维奈克拉联合减低剂量HAD诱导方案，1个疗程完全缓解率高，安全性良好。